Background: Hormonal factors have long been proposed to play a role in Behçet’s disease (BD). Male sex, systemic onset, HLA-B51 positivity and a younger age of onset in BD are associated with severer disease, and the disease generally runs a milder course in women. Vascular involvement is more common, and the skin pathergy test (SPT) is more strongly positive in men. BD rarely develops before puberty or after the age of 50 years. Clinical manifestations of the disease, with the exception of eye symptoms, tend to improve with time. Therefore, BD may be androgen driven to some degree. Objectives: We aimed to investigate androgen receptor (AR) levels of oral ulcers (OU), genital ulcers (GU) and SPT areas and compared them with those of adjacent normal-appearing skin/mucosa from patients with BD. Methods: Thirty-eight patients with BD (16 female, 22 male; mean ± SD age, 36.45 ± 10.2 years), diagnosed according to the criteria of the International Study Group for Behçet’s Disease, were included in the study with blind histological examination. Biopsies from OU of 10 patients, GU of 11 patients, SPT areas of 17 patients and adjacent (approximately 2 cm distant) normal-appearing skin/mucosa in patients with BD were performed. Nuclear AR levels were studied by an immunohistochemical technique, using monoclonal antibodies. The percentage of positively staining cells was recorded as the AR index (ARI). In addition, the prevalence and the positivity rate of SPT has also been evaluated. Results: ARI values in the lesional and control (non-lesional adjacent) skin/mucosa were found to be 14.5 versus 18% for OU, 28.7 versus 25.5% for GU and 36.3 versus 21.8% (p = 0.068) for SPT areas. The positive SPT areas in male patients showed a higher ARI than those of female patients (43.36 and 23.33%; p = 0.078). The ARI values of SPT areas in male patients but not in female patients were found to be significantly higher as compared with non-lesional skin (21.63%; p = 0.039). The SPT positivity was also more common in male patients compared with female patients (86.4% and 62.5%), although the difference was not significant (p = 0.88). SPT have been found to be more strongly positive among the males (4.63 ± 3.3) compared with female patients (3.18 ± 1.9), and the difference was statistically significant (p = 0.022). Conclusions: Our findings indicate that androgens seem to play a role both in the formation and increased positivity of the SPT areas in male patients with BD.

1.
Alpsoy E, Kodelja V, Goerdt S, Orfanos CE, Zouboulis CC: Serum of patients with Behçet’s disease induces classical (pro-inflammatory) activation of human macrophages in vitro. Dermatology 2003;206:225–232.
2.
Zouboulis CC, May T: Pathogenesis of Adamantiades-Behcet’s disease. Med Microbiol Immunol 2003;192:149–155.
3.
Zouboulis CC, Turnbull JR, Martus P: Univariate and multivariate analyses comparing demographic, genetic, clinical, and serological risk factors for severe Adamantiades-Behçet’s disease; in Zouboulis CC (ed): Adamantiades-Behçet’s Disease. London/Amsterdam, Plenum/Kluwer, 2003, pp 123–126.
4.
Yazici H, Tuzun Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdogan H, Serdaroglu S, Ersanli M, Ulku BY, Muftuoglu AU: Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behçet’s syndrome. Ann Rheum Dis 1984;43:783–789.
5.
Demiroglu H, Barista I, Dundar S: Risk factor assessment and prognosis of eye involvement in Behçet’s disease in Turkey. Ophthalmology 1997;104:701–705.
6.
Yazici H, Mat C, Deniz S, Iscimen A, Yurdakul S, Tuzun Y, Hekim N, Yazici Y: Sebum production is increased in Behçet’s syndrome and even more so in rheumatoid arthritis. Clin Exp Rheumatol 1987;5:371–374.
7.
Uzun S, Alpsoy E, Durdu M, Akman A: The clinical course of Behçet’s disease in pregnancy: A retrospective analysis and review of the literature. J Dermatol 2003;30:499–502.
8.
International Study Group for Behçet’s Disease: Criteria for diagnosis of Behçet’s disease. Lancet 1990;i:1078–1080.
9.
Yazici H, Tuzun Y, Tanman AB, Yurdakul S, Serdaroglu S, Pazarli H, Muftuoglu A: Male patients with Behcet’s syndrome have stronger pathergy reactions. Clin Exp Rheumatol 1985;3:137–141.
10.
Alpsoy E, Zouboulis CC, Ehrlich CE: Mucocutaneous lesions of Behçet’s disease. Yonsei Med J, in press.
11.
Fresko I, Yazici H, Bayramicli M, Yurdakul S, Mat C: Effect of surgical cleaning of the skin on the pathergy phenomenon in Behçet’s syndrome. Ann Rheum Dis 1993;52:619–620.
12.
Dilsen N, Konice M, Aral O, Ocal L, Inanc M, Gul A: Comparative study of the skin pathergy test with blunt and sharp needles in Behçet’s disease: Confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis 1993;52:823–825.
13.
Durusoy C, Alpsoy E, Elpek O, Karpuzoglu G: Histological findings and androgen receptor levels in the sebaceous glands of papulopustular lesions from patients with Behçet’s disease and acne vulgaris: A controlled study. Adv Clin Pathol 2002;6:87–93.
14.
Mat C, Demirkesen C, Cokerler OA, Çetiner B, Fresko I, Yurdakul S, Tuzun Y, Yazıcı H: Behçet sendromunda skrotal deride androjen reseptör yoğunluğu. 17. Ulusal Dermatoloji Kongresi, Kuşadası, 1998.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.